SIGY Stock Overview
A development-stage company, provides therapeutic solutions in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sigyn Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.75 |
| 52 Week High | US$11.20 |
| 52 Week Low | US$3.00 |
| Beta | -1.07 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -48.66% |
| 33 Year Change | -82.03% |
| 5 Year Change | n/a |
| Change since IPO | -92.70% |
Recent News & Updates
Recent updates
Shareholder Returns
| SIGY | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.9% |
| 1Y | -48.7% | 20.8% | 32.3% |
Return vs Industry: SIGY underperformed the US Medical Equipment industry which returned 20.8% over the past year.
Return vs Market: SIGY underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| SIGY volatility | |
|---|---|
| SIGY Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: SIGY has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SIGY's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 5 | Jim Joyce | www.sigyntherapeutics.com |
Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines.
Sigyn Therapeutics, Inc. Fundamentals Summary
| SIGY fundamental statistics | |
|---|---|
| Market cap | US$7.27m |
| Earnings (TTM) | -US$3.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs SIGY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SIGY income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$3.70m |
| Earnings | -US$3.70m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.93 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -50.4% |
How did SIGY perform over the long term?
See historical performance and comparison